1. Academic Validation
  2. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

  • Bioorg Chem. 2019 Nov;92:103209. doi: 10.1016/j.bioorg.2019.103209.
Zheng Li 1 Qiang Ren 1 Xuekun Wang 2 Zongtao Zhou 1 Lijun Hu 1 Liming Deng 1 Li Guan 3 Qianqian Qiu 4
Affiliations

Affiliations

  • 1 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China.
  • 2 College of Pharmacy, Liaocheng University, Liaocheng 252059, PR China.
  • 3 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: guanli@gdpu.edu.cn.
  • 4 School of Pharmacy, Jiangsu Provincial Key Laboratory of Coastal Wetland Bioresources and Environmental Protection, Yancheng Teachers' University, Yancheng, PR China. Electronic address: qianqianqiu_cpu@126.com.
Abstract

Based on a previously reported phenoxyacetic acid scaffold, compound 7 (HWL-088) has been identified as a superior Free Fatty Acid Receptor 1 (FFA1) agonist by comprehensive structure-activity relationship study. Our results indicated that the introduction of ortho-fluoro greatly increased the activity of phenoxyacetic acid series, and the unique structure-activity relationship in biphenyl moiety is different from previously reported FFA1 agonists. Moreover, the modeling study was also performed to better understand the binding mode of present series. Compound 7 significantly improved glucose tolerance both in normal and diabetic models, and even exerted greater potential on glucose control than that of TAK-875. These findings provided a novel candidate HWL-088, which is currently in preclinical study to evaluate its potential for the treatment of diabetes.

Keywords

Diabetes; FFA1; GPR40; Hyperglycemia; Phenoxyacetic acid.

Figures
Products